BPC-157: Structure, Stability and Research Overview

BPC-157 is a synthetic 15-amino-acid peptide (a pentadecapeptide) whose sequence is derived from a protein found in human gastric juice. In preclinical work it has been studied mostly in endothelial cell, isolated vessel and rodent tissue models, where it has been associated with nitric-oxide and VEGF-related signaling. It is not an approved drug, and the evidence base is entirely preclinical.

Molecular identity

A few features of the sequence matter for lab work:

• Proline-rich N-terminal half. The run of three consecutive prolines (Pro3–Pro5), plus a fourth at position 8, limits conformational flexibility and gives that half of the molecule a distinctive, relatively rigid backbone.
• Net negative charge at neutral pH. Three acidic side chains (Glu2, Asp10, Asp11) plus the C-terminal carboxyl outweigh the single lysine and the N-terminal amine.
• No cysteine or methionine. That rules out disulfide scrambling and methionine oxidation, two common degradation routes in other peptides.

On electrospray mass spectrometry BPC-157 commonly appears as the doubly protonated ion [M+2H]²⁺ near m/z 710 as well as the singly charged ion. A COA may report either.

Origin and stability

The University of Zagreb group behind most of the published work calls BPC-157 a "stable gastric pentadecapeptide". It describes the peptide as formed in the gastric mucosa and stable in human gastric juice [1]. That description concerns behavior in a biological fluid. It is not a shelf-life specification for research material, which depends on lyophilization, counter-ion and storage conditions.

Synthetic BPC-157 is usually isolated as a salt, commonly an acetate or trifluoroacetate. The counter-ion and residual water add to the mass in the vial, so the net peptide content is lower than the gross powder weight. This is one reason a COA's purity figure (by HPLC) and a vial's fill weight answer different questions.

What the research has examined

Blood vessels and angiogenesis

A 2014 review from the originating group covers BPC-157's reported effects on blood vessels across its models: endothelial damage, clotting, vasoconstriction and vasodilation, new vessel formation and edema. It describes BPC-157 as acting through several vasoactive pathways, including nitric oxide, VEGF and FAK [2]. A 2026 critical review of rodent ischemia–reperfusion studies likewise reported changes in VEGF/VEGFR2–Akt–eNOS-related signaling across that literature [3]. Both are secondary sources. The review from the originating group summarizes that group's own work.

Vasomotor tone and nitric oxide

In isolated rat aorta, BPC-157 produced a concentration-dependent vasodilation. The effect was reduced when the endothelium was removed and inhibited by L-NAME or hemoglobin, which points to a nitric-oxide-mediated mechanism. In endothelial cells it increased phosphorylation of Src, Caveolin-1 and eNOS and reduced Caveolin-1–eNOS binding [4]. The Zagreb group has separately reviewed the relationship between BPC-157 and the nitric oxide system across its own rat models [1], and has examined BPC-157 alongside L-NAME and L-arginine in a rat cecal perforation model [5].

Isolated human arterial tissue

A 2026 ex vivo study used segments of human internal mammary artery left over from surgery. In arterial rings pre-contracted with phenylephrine, BPC-157 produced concentration-dependent relaxation that was greater in rings with intact endothelium. The NOS inhibitor L-NAME attenuated it. The authors concluded that the effect is mainly mediated by an endothelium-dependent nitric oxide pathway, with some residual effect pointing to additional mechanisms, and that further molecular and in-vivo work is needed [6]. This agrees with the earlier rat aorta work [4].

Central nervous system models

A 2022 review from the originating group summarized rat studies in models of carotid artery occlusion, chemically induced catalepsy, schizophrenia-like behavior models and spinal cord compression [7]. These are reviews of the group's own work and should be read as such.

Strength of the evidence

Two points matter when you read this literature:

1. Concentration of authorship. A large share of the in-vivo BPC-157 literature comes from one research group. Independent replication is limited.
2. Preclinical only. A 2026 critical review of rodent ischemia–reperfusion studies called the evidence heterogeneous. It noted short observation periods and incompletely characterized risk of bias, and it described BPC-157 as a hypothesis-generating candidate for further preclinical research. It called for independent blinded replication, pharmacokinetic characterization and further preclinical characterization [3]. BPC-157 is not an approved drug.

Analytical verification

For a 15-mer like BPC-157, a reverse-phase HPLC trace should show one dominant main peak. Deletion sequences (missing one residue) are the most common synthesis impurities and tend to elute close to it. Mass spectrometry should confirm 1419.5 Da, or the corresponding charge states. Our guides to HPLC purity and reading a certificate of analysis walk through both. Batch documents for every lot are in the COA registry.

Storage and handling

Store lyophilized BPC-157 at −20 °C, away from light and moisture, and let the vial reach room temperature before opening so moisture doesn't condense on the powder. After reconstitution, keep the solution at 2–8 °C and avoid repeated freeze–thaw cycles. Handle it as laboratory material throughout.

Common questions

Is BPC-157 a naturally occurring peptide?

Not as supplied. BPC-157 is made by chemical synthesis. Its sequence is described as originating in the gastric mucosa [1], but the 15-residue peptide sold for research is a synthetic product, confirmed by HPLC and mass spectrometry rather than isolated from a biological source.

Why do papers write "BPC 157" without the hyphen?

It's the same compound. Much of the primary literature, including the papers cited here, writes "BPC 157" or "BPC157". Supplier catalogs usually use "BPC-157". Use CAS 137525-51-0 when you need an unambiguous identifier.

Related material

• BPC-157 and BPC-157, Made in USA
• BPC-157 + TB-500 blend
• BPC-157 vs TB-500: a side-by-side comparison
• BPC-157 is also a component of the KLOW and GLOW blends (KLOW vs GLOW)

References

1. Sikiric P, et al. Stable gastric pentadecapeptide BPC 157-NO-system relation. Curr Pharm Des. 2014. PubMed
2. Seiwerth S, et al. BPC 157 and blood vessels. Curr Pharm Des. 2014. PubMed
3. Demirtaş H. BPC 157 in Rodent Ischemia-Reperfusion Injury: A Critical Review of Preclinical Evidence. Int J Mol Sci. 2026. PubMed
4. Hsieh MJ, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020. PubMed
5. Drmic D, et al. Counteraction of perforated cecum lesions in rats: Effects of pentadecapeptide BPC 157, L-NAME and L-arginine. World J Gastroenterol. 2018. PubMed
6. Yildirim AK, et al. Endothelium-Dependent Nitric Oxide-Mediated Vasorelaxant Effects of BPC 157 in Human Internal Mammary Artery. J Clin Med. 2026. PubMed
7. Vukojevic J, et al. Pentadecapeptide BPC 157 and the central nervous system. Neural Regen Res. 2022. PubMed